Back
PTC Therapeutics 10K Form
Buy
55
PTCT
PTC Therapeutics
Last Price:
41.83
Seasonality Move:
12.84%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-08-05 | 10Q | PTCT/PTC Therapeutics Quarterly |
2020-04-30 | 10Q | PTCT/PTC Therapeutics Quarterly |
2020-03-02 | 10K | PTCT/PTC Therapeutics Annual |
2019-10-30 | 10Q | PTCT/PTC Therapeutics Quarterly |
2019-08-06 | 10Q | PTCT/PTC Therapeutics Quarterly |
2019-05-02 | 10Q | PTCT/PTC Therapeutics Quarterly |
Receive PTCT News And Ratings
See the #1 stock for the next 7 days that we like better than PTCT
PTCT Financial Statistics
Sales & Book Value
Annual Sales: | $538.59M |
---|---|
Cash Flow: | $-178.85M |
Price / Cash Flow: | 0 |
Annual Sales: | $-1.27 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -7.38000 |
---|---|
Net Income (TTM): | $-521.99M |
Gross Margin: | $506.27M |
Return on Equity: | -516.88% |
Return on Assets: | -26.32% |
PTC Therapeutics Earnings Forecast
Key PTC Therapeutics Financial Ratios
- The Gross Profit Margin over the past 9 years for PTCT is 94.00%.
- The Selling, General & Administrative Expenses for PTCT have been equal to 53.06% of Gross Profit Margin.
- The Research & Development expenses have been 100.39% of Revenue.
- The Interest Expense is -16.42% of Operating Income.
- The Net Earning history of PTCT is -97.27% of Total Revenues.
- Per Share Earnings over the last 11 years have been positive in 4 years.
PTC Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Healthcare |
Current Symbol: | PTCT |
CUSIP: | 69366J |
Website: | ptcbio.com |
Debt
Debt-to-Equity Ratio: | -4.77 |
---|---|
Current Ratio: | 1.62 |
Quick Ratio: | 1.53 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
PTCT Technical Analysis vs Fundamental Analysis
Buy
55
PTC Therapeutics (PTCT)
is a Buy
Is PTC Therapeutics a Buy or a Sell?
-
PTC Therapeutics stock is rated a Buy
The current PTC Therapeutics [PTCT] share price is $41.85. The Score for PTCT is 55, which is 10% above its historic median score of 50, and infers lower risk than normal.